Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 20/20 | 0.60 |
| ▸ | S1PR3 | Q99500 | 19/20 | 0.60 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3405045 | 0.91 | S1PR1 (0.57) | S1PR1S1PR3S1PR5 | |
| SCHEMBL3408011 | 0.91 | S1PR1 (0.66) | S1PR1S1PR3 | |
| SCHEMBL3783587 | 0.90 | S1PR1 (0.57) | S1PR1S1PR3 | |
| SCHEMBL3402308 | 0.90 | S1PR1 (0.57) | S1PR1S1PR3S1PR5 | |
| SCHEMBL3408153 | 0.86 | S1PR1 (0.55) | S1PR1S1PR3S1PR5 | |
| SCHEMBL3407949 | 0.86 | S1PR1 (0.55) | S1PR1S1PR3S1PR5 | |
| SCHEMBL3408752 | 0.82 | S1PR1 (0.61) | S1PR1S1PR3 | |
| SCHEMBL3408630 | 0.79 | S1PR1 (0.68) | S1PR1S1PR3 | |
| SCHEMBL3406459 | 0.78 | S1PR1 (0.66) | S1PR1S1PR3 | |
| SCHEMBL3407733 | 0.78 | S1PR1 (0.71) | S1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102015695-B | Pyridin-2-yl derivatives as immunomodulating agents | ACTELION PHARMACEUTICALS LTD | 2014-08-27 | — | — | CN | disclosed |
| US-8575200-B2 | Pyridin-2-yl derivatives as immunomodulating agents | ACTELION PHARMACEUTICALS LTD (CH) | 2013-11-05 | — | — | US | disclosed |
| EP-2252609-B1 | PYRIDIN-2-YL DERIVATIVES AS IMMUNOMODULATING AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-04-17 | — | — | EP | disclosed |
| CN-102015695-A | Pyridin-2-yl derivatives as immunomodulating agents | ACTELION PHARMACEUTICALS LTD | 2011-04-13 | — | — | CN | disclosed |
| US-20100331372-A1 | PYRIDIN-2-YL DERIVATIVES AS IMMUNOMODULATING AGENTS | VIATRIS ASIA PACIFIC PTE. LTD. (SG) | 2010-12-30 | — | — | US | disclosed |
| EP-2252609-A1 | PYRIDIN-2-YL DERIVATIVES AS IMMUNOMODULATING AGENTS | Actelion Pharmaceuticals Ltd. (CH) | 2010-11-24 | — | — | EP | disclosed |
| WO-2009109872-A1 | PYRIDIN-2-YL DERIVATIVES AS IMMUNOMODULATING AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331372-A1 | PYRIDIN-2-YL DERIVATIVES AS IMMUNOMODULATING AGENTS | IL2, FCGRT, CD4 | S1PR1 94/4885S1PR3 104/4885S1PR5 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.